McGuireWoods advised vVARDIS, a Swiss high-growth dental company, in a $35 million financing with OrbiMed, a leading healthcare investment firm. The capital will support vVARDIS’ growth initiatives and global commercial expansion.
vVARDIS is a developer and manufacturer of non-invasive dental products under the Curodont brand. Thousands of dental clinics in the United States and European Union employ vVARDIS products in their practices, which also are incorporated in lectures at renowned universities in the United States and Europe as an emerging option for the management of early tooth decay.
McGuireWoods partner Jeff Goldfarb and associate Allyson Maur represented vVARDIS in the transaction.
“We were pleased to assist vVARDIS in this important transaction, which will enable the company to expand and provide more innovative solutions to dental professionals and patients,” Goldfarb said.
McGuireWoods is a dominant player in private equity and finance transactions involving a range of healthcare services. The firm earned nationwide rankings for its healthcare, M&A, and private equity capabilities from Chambers USA and the Legal 500 United States.